NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Neonc Technologies Holdings, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Oct 21, 2026NEO100
- Phase 2Recruiting
NEO100 and High-Grade Meningioma
NEO100
Residual, Progressive or Recurrent Grade II or III Meningioma
NCT05023018Enrollment30StartJul 2022Primary CompletionDec 2026est.CompletionJun 2027est. - Phase 1/2Active, not recruiting
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Perillyl alcohol
Glioblastoma Multiforme
NCT02704858Enrollment49StartAug 2017Primary CompletionNov 2026est.CompletionDec 2026est. - Phase 1/2Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NEO212 Oral Capsule, Ipilimumab
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype +19
NCT06047379Enrollment134StartNov 2023Primary CompletionFeb 2027est.CompletionAug 2027est. - Phase 1Recruiting
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
NEO100
Pediatric Tumor of CNS, Pediatric Tumor of Brain +6
NCT06357377Enrollment12StartSep 2026Primary CompletionJun 2027est.CompletionJul 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Recruiting | NEO100 | NCT05023018 |
| Phase 1/2 | Active, not recruiting | Perillyl alcohol | NCT02704858 |
| Phase 1/2 | Recruiting | NEO212 Oral Capsule, Ipilimumab | NCT06047379 |
| Phase 1 | Recruiting | NEO100 | NCT06357377 |